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producing CD4+ T cells in controlled
human malaria infection studies. These
results provide a potential explanation for
why vaccines may function sub-optimally
in disease-endemic areas.
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The development of immunoregulatory networks is
important to prevent disease. However, these same
networks allow pathogens to persist and reduce
vaccine efficacy. Here, we identify type I interferons
(IFNs) as important regulators in developing anti-
parasitic immunity in healthy volunteers infected for
the first time with Plasmodium falciparum. Type I
IFNs suppressed innate immune cell function and
parasitic-specific CD4+ T cell IFNg production, and
they promoted the development of parasitic-specific
IL-10-producing Th1 (Tr1) cells. Type I IFN-depen-
dent, parasite-specific IL-10 production was also
observed in P. falciparummalaria patients in the field
following chemoprophylaxis. Parasite-induced IL-10
suppressed inflammatory cytokine production, and
IL-10 levels after drug treatment were positively
associated with parasite burdens before anti-para-
sitic drug administration. These findings have impor-
tant implications for understanding the development
of host immune responses following blood-stage
P. falciparum infection, and they identify type I IFNs
and related signaling pathways as potential targets
for therapies or vaccine efficacy improvement.
INTRODUCTION
Eliminating pathogens typically requires the generation of robust
host immune responses. However, these responses need to beCe
This is an open access article under the CC BY-Ntightly controlled so that they do not damage host tissues. There-
fore, humans have developed potent immunoregulatory net-
works to control inflammation and prevent disease (Chaudhry
and Rudensky, 2013; Engwerda et al., 2014; Sakaguchi et al.,
2008, 2013). Many pathogens take advantage of these immuno-
regulatory mechanisms to persist in their host (Belkaid and
Rouse, 2005). In the case of parasites that cause diseases
such as malaria, toxoplasmosis, and leishmaniasis, persistent
infection can also maintain concomitant immunity, which may
be especially important in protecting against new infections
with pathogenic parasite strains in disease-endemic areas
(Sacks, 2014). A better understanding of how immunoregulatory
networks develop and are maintained following infection is
needed if they are to be manipulated for therapeutic advantage
or to improve vaccine efficiency.
Malaria remains a significant global health problem, with more
than 250 million cases and 500,000 deaths annually (WHO,
2014). Plasmodium falciparum is responsible for most of this
morbidity andmortality, with young children being most affected
(WHO, 2014). Results with the RTS,S/AS01 vaccine show that
despite having approximately 50% vaccine efficacy in healthy
volunteers participating in controlled human malaria infection
(CHMI) studies (Kester et al., 2009; Ockenhouse et al., 2015), ef-
ficacy fell when tested in healthy adults living in a high malaria
transmission region (Polhemus et al., 2009) and provided similar,
relatively modest protection in children living in malaria-endemic
areas (Rts, 2015). The reason for this difference is not clear, but
this phenomenon has also been observed with other vaccines,
such as those developed to protect against tuberculosis (Pitt
et al., 2013; Skeiky and Sadoff, 2006), respiratory syncytial virus
(RSV) (Christiaansen et al., 2014), and HIV (Boussiotis et al.,
2000; Migueles and Connors, 2015; Rodrı´guez-Garcı´a et al.,ll Reports 17, 399–412, October 4, 2016 ª 2016 The Author(s). 399
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2011). One possible explanation is that early exposure to
pathogens promotes the development of immunoregulatory net-
works that impede the generation of efficient vaccine-induced
immunity.
A number of regulatory molecules and cell populations have
been identified in pre-clinical models of malaria, as well as in
malaria patients. These include cytokines such as interleukin
(IL) 10 (Couper et al., 2008; Plebanski et al., 1999) and transform-
ing growth factor b (TGF-b) (Omer and Riley, 1998; Walther et al.,
2005), as well as immune checkpoint molecules such as CTLA-4
(Jacobs et al., 2002; Schlotmann et al., 2000), LAG-3 (Butler
et al., 2011; Illingworth et al., 2013), PD-1 (Butler et al., 2011;
Hafalla et al., 2012), and TIM-3 (Costa et al., 2015; Huang
et al., 2013). Specialized sub-populations of CD4+ T cells have
emerged as major regulators of inflammation during parasitic
diseases (Belkaid and Rouse, 2005; Engwerda et al., 2014).
These regulatory T (Treg) cells can be broadly divided into two
types. First, natural Treg cells are produced in the thymus and
express the transcription factor FoxP3 that is critical for their
suppressive functions (Sakaguchi et al., 2013). Treg cells with
increased suppressive function have been reported in adults
with malaria (Minigo et al., 2009; Walther et al., 2005). However,
studies in African children showed that neither Treg cell number
nor Treg cell function differs between patients with uncompli-
cated malaria and those with severe malaria (Walther et al.,
2009). A study of Ugandan children from areas of different ma-
laria exposure indicated that burden of disease may have an
important impact on number and function of Treg cells (Boyle
et al., 2015). Furthermore, a study in malaria patients from the
Peruvian Amazon showed that neither Treg cell frequency nor
Treg cell number was associated with the risk of malaria-related
symptoms (Torres et al., 2014), suggesting that alternative
mechanisms of immune regulation may be important for control-
ling inflammation and thus preventing disease.
A second type of Treg cell consists of inducible Treg cells,
which emerge from the thymus as conventional CD4+ T cells
but develop regulatory functions in the periphery following
exposure to appropriate inflammatory stimulation. These include
IL-10-producing T helper 1 (Th1) or type I regulatory (Tr1) cells
(O’Garra et al., 2004). Tr1 cells, but not Treg cells, were shown
to be more prevalent in Gambian children with uncomplicated
malaria compared to those with severe disease (Walther et al.,
2009). Furthermore, Tr1 cells emerge relatively quickly in chil-
dren living in malaria-endemic areas (Jagannathan et al., 2014;
Portugal et al., 2014), but their role in suppressing either inflam-
mation or anti-parasitic immunity remains unclear.
Type I interferons (IFNs) have emerged as important immune
regulators in infectious disease (McNab et al., 2015). They are
required for anti-viral defenses but can also promote pathogen
survival by suppressing immunity during infections, such as
those caused by lymphocytic choriomeningitis virus (Teijaro
et al., 2013; Wilson et al., 2013), influenza (Arimori et al., 2013),
Mycobacteria (Antonelli et al., 2010; Berry et al., 2010; Desvignes
et al., 2012; Stanley et al., 2007; Teles et al., 2013), Listeria (Auer-
buch et al., 2004; Carrero et al., 2004), Staphylococcus (Parker
and Prince, 2012), Leishmania (Xin et al., 2010), and Plasmodium
(Haque et al., 2011; Sharma et al., 2011). In mice infected with
Mycobacteria tuberculosis, type I IFNs suppressed inflammatory400 Cell Reports 17, 399–412, October 4, 2016cytokine production by stimulating the production of IL-10 and
IL-1 receptor antagonists (Mayer-Barber et al., 2011; McNab
et al., 2014). We reported that type I IFNs inhibited the ability
of dendritic cells (DCs) to activate CD4+ T cells in experimental
murine malaria models, and this was associated with changes
in co-stimulatory molecule expression, as well as the promotion
of DC IL-10 production (Haque et al., 2011, 2014).
To understand better how and when regulatory mechanisms
develop during malaria, we examined peripheral blood from hu-
man volunteers participating in CHMI studies with P. falciparum
3D7. We identified type I IFNs as major immunoregulatory mole-
cules during blood-stage malaria. We show that they sup-
pressed innate and adaptive immunity, as well as promoting
the generation of Tr1 cells following resolution of infection with
an anti-parasitic drug.We also show that IL-10 production by pe-
ripheral blood mononuclear cells (PBMCs) from P. falciparum
malaria patients collected in the field were regulated by type I
IFNs. These results provide insights into the development of im-
munity during malaria and provide a potential explanation for
why vaccines administered in disease-endemic areas may func-
tion sub-optimally.
RESULTS
CD4+ T Cell Responses during Blood-Stage
P. falciparum Infection
To understand how CD4+ T cells respond following first expo-
sure to P. falciparum, we isolated PBMCs at various times
throughout CHMI studies involving multiple cohorts in the
context of various clinical trials of new anti-malaria drugs. Infec-
tion in healthy volunteers was established by intravenous injec-
tion of 1,800 P. falciparum 3D7 parasitized red blood cells
(pRBCs), with drug treatment initiated when blood parasitemia,
determined by qPCR (Rockett et al., 2011), was greater than
1,000 parasites/mL (Figure 1A). This occurred on either day 7
or day 8 post-infection (p.i.), at which time most volunteers
showed no clinical signs of malaria.
First, we measured the ability of PBMCs to produce the pro-
inflammatory cytokine IFNg in response to parasite antigen
throughout the study period (Figures 1A and 1B). As reported
by others (Good, 1994; Ndungu et al., 2006), we observed
some IFNg production by PBMCs from volunteers before infec-
tion, presumably by memory T cells generated in response to
cross-reactive antigens from other pathogens (Currier et al.,
1995). IFNg production in response to parasite antigen was
also significantly increased relative to controls (normal red blood
cells [nRBC]) 7 days after infection and further increased 7 days
after the commencement of drug treatment and maintained until
at least 28 days after infection, albeit at decreased levels at the
latter time point (Figure 1B).
T cells were a major source of IFNg measured in this assay,
although natural killer (NK) cells and other lymphocytes also pro-
duced IFNg, as indicated by analysis of the frequency of IFNg-
producing cells in PBMC cultures isolated during the study
period (Figures S1A and S1B). However, CD4+ T cells accounted
for substantial amounts of cytokine in most volunteers, because
when major histocompatibility complex (MHC) class II antigen
presentation was blocked in PBMC cultures at day 7 p.i., the
Figure 1. Blood-Stage P. falciparum Infection
Induces Parasite-Specific CD4+ T Cell Re-
sponses
(A) Volunteers were injected with 1,800 pRBCs/mL,
and blood parasitemia was monitored by PCR
beginning day 4 p.i. until day 35 p.i. (cohort 6; n = 7).
Drug treatment commenced on day 7 p.i. (as shown
by the arrow).
(B) PBMCs were isolated from participants
throughout infection and cultured in the presence of
nRBCs or pRBCs as indicated for 72 hr, and then cell
culture supernatants were harvested and IFNg levels
were measured (cohorts 6–8; n = 16).
(C) PBMCs were isolated from participants 7 days
p.i. and cultured in the presence of pRBCs and anti-HLADR antibody or its isotype control for 72 hr, and then cell culture supernatants were harvested and IFNg
levels were measured (cohorts 9 and 10; n = 13).
(D) The frequencies of CD4+ and CD8+ T cells in PBMCs isolated from volunteers at day 0 (D0) and day 7 (D7) p.i. were measured by flow cytometry (cohorts 1–5;
n = 33).
Mean ± SEM (A, B, and D), median + min and max (C). ***p < 0.001, **p < 0.01, Wilcoxon matched-pairs signed rank test. See also Figure S1.amount of IFNg produced was significantly diminished (Fig-
ure 1C). The frequency of CD4+ or CD8+ T cells in the blood of
volunteers at this time point was relatively unchanged (Fig-
ure 1D). Altogether, these data show that parasite-reactive
CD4+ T cell responses could be detected throughout the course
of infection and were greatest 7 days after commencement of
drug treatment.
Type I IFNs Produced in Response to P. falciparum
Suppress CD4+ T Cell IFNg Production
Previously, we reported that type I IFNs suppressed anti-para-
sitic Th1 cell responses in experimental models of malaria (Ha-
que et al., 2011, 2014). Parasite-stimulated IFNa2 was produced
in response to P. falciparum antigen throughout the course of
infection and was significantly elevated at day 7 p.i. (Figure 2A).
We next investigated the cellular sources of type I IFNs at day 7
p.i. and found that although plasmacytoid dendritic cells (pDCs;
HLA-DR+ CD123+ CD304+) were a major source of this cytokine
in response to CpG, other cell types were also capable of type I
IFN production (Figure S2). Furthermore, multiple cell types were
able to produce IFNa species when cultured with nRBC or pRBC
(Figure 2B). We also found that multiple type I IFNs were ex-
pressed by different PBMC populations isolated from PBMCs
at 7 days p.i. (Figure S3). Thus, increased type I IFN production
in response to P. falciparum infection comes from different
cell sources and results from increased expression of multiple
type I IFN species.
When type I IFN signaling was blocked with an antibody reac-
tive against type I IFN receptor, antigen-specific IFNg production
was significantly increased at day 7 p.i. (Figure 3A), but this effect
was not observed before infection or after commencement of
drug treatment (data not shown). Although the frequencies of
IFNg-producing cell populations were relatively unchanged after
type I IFN blockade (Figures S1B and S1C), the increased IFNg
production by PBMCs at day 7 p.i., following type I IFN blockade,
appeared to be largely MHC class II antigen dependent (Fig-
ure 3B). We next examined the relationship between parasite-
specific IFNg levels at day 7 p.i. and parasite burdens in volun-
teers over the interval before drug treatment, as assessed by
the area under the curve (AUC) of blood parasitemia. This re-vealed a significant inverse correlation between IFNg levels
and parasite burden (Figure 3C). In addition, analysis of IFNg
mean fluorescence intensity (MFI) showed that type I IFN
blockade significantly increased IFNg expression by CD4+
T cells but not by other IFNg-producing cell populations (Fig-
ure 3D). Hence, type I IFNs produced during first exposure to
P. falciparum suppressed the ability of parasite-specific CD4+
T cells to produce IFNg. We observed similar effects on IL-17,
IL-1b, and IL-6 production but not on tumor necrosis factor
(TNF) production (Figure 4), suggesting some level of specificity
for the suppressive effects of type I IFNs.
Type I IFNs Inhibit Parasite-Mediated IL-6 Production by
Monocytes
The effect of type I IFN blockade on IL-6 production following
exposure of PBMCs to parasite antigen was especially pro-
nounced before infection, with a greater than 100-fold increase
in IL-6 production upon type I IFN blockade (Figure 4A). This sug-
gested that parasite-induced type I IFNs may target innate cell
populations. fluorescence-activated cell sorting (FACS) analysis
(Figure 5A) revealed that most of this IL-6 came from DCs (Fig-
ures 5B and 5C) and monocytes, with the latter cell population
producing most of this cytokine on an individual cell basis (Fig-
ure 5D). Strikingly, IL-6 production by monocytes, but not by
DC subsets, was significantly affected by type I IFN blockade,
indicating a selective effect of type I IFNs on monocytes
following exposure to P. falciparum. Thus, in addition to regu-
lating CD4+ T cell responses during sub-clinical malaria, type I
IFNs suppressed early inflammatory responses by innate im-
mune cells following exposure to parasites.
Type I IFNs Promote the Development of
Immunosuppressive Antigen-Specific Tr1 Cells after
Anti-parasitic Drug Treatment
Tr1 cells have emerged as a dominant CD4+ T cell response in
highly exposed children living in malaria-endemic regions (Ja-
gannathan et al., 2014; Portugal et al., 2014; Walther et al.,
2009). We found significant levels of IL-10 production by PBMCs
in response to parasite antigen 7 days after drug treatment was
initiated (14 days p.i.) (Figure 6A). This was not related to the typeCell Reports 17, 399–412, October 4, 2016 401
Figure 2. Blood-Stage P. falciparum Induces
IFNa Production upon First Exposure and Is
Produced by Various Cell Types
(A) PBMCs from volunteers at days 0, 7, and 14 p.i.
were cultured in the presence of nRBCs or pRBCs
for 72 hr, and then cell culture supernatants were
harvested and IFNa levels were measured (cohort
10; n = 7).
(B) Cryopreserved PBMCs from volunteers at day
0 (D0) or 7 (D7) p.i. were cultured in the presence of
nRBCs or pRBCs for 6 hr (as indicated), and then
cellular sources of IFNa was measured by intracel-
lular cytokine staining (cohorts 9–10; n = 6). Total
IFNa+ events were gated first, and then cell types
were gated as shown in Figure S2, using CpG as a
positive control for IFNa staining. Not all samples
from these cohorts were used in this assay, because
a limited number of samples were cryopreserved.
Median + min and max. *p < 0.05, Wilcoxon
matched-pairs signed rank test.of drug used to treat the P. falciparum infection, because the
same response was observed when different drugs were used
(Figures 6A–6C, 7A, and 7B; Table 1), as was the case for all im-
mune parameters examined. The increased parasite-specific
IL-10 production was associated with a significant increase in
the frequency of Tr1 cells at this time point (Figures 6B and
6C). CD4+ T cells were an important source of IL-10 in these
cell cultures, because MHC class II blockade significantly
reduced both frequency of Tr1 cells and IL-10 levels in culture
supernatants (Figures 6C and 6D). Blockade of type I IFN
signaling had a similar effect (Figures 7A and 7B), consistent
with the idea that parasite-induced type I IFNs promoted the
generation of Tr1 cells and/or IL-10 production by these cells.
Hence, type I IFNs not only suppressed parasite-specific IFNg
production by CD4+ T cells during sub-microscopic, pre-symp-
tomatic Plasmodium infection but also contributed to the gener-
ation of Tr1 cells following anti-parasitic drug treatment.
To explore the functional consequences of increased IL-10
production, we examined the relationship between IL-10 levels
and parasite burdens. A significant, positive correlation between
the amount of IL-10 produced after drug treatment and the
parasite burdens in volunteers over the interval before treatment,
as assessed by the AUC of blood parasitemia, was found (Fig-
ure 7C). However, we cannot determine whether increased IL-
10 at this time point indicates earlier immune suppression that
allowed increased parasite growth or increased parasite bur-
dens promoted the development of more Tr1 cells and/or IL-
10 production. Nevertheless, IL-10 produced in response to
parasite antigen 7 days after drug treatment suppressed para-
site-specific inflammation, as indicated by increased parasite-
specific IFNg and TNF production when IL-10 was blocked in
PBMC cultures (Figures 7D and 7E). Finally, to test whether
type I IFNs promoted IL-10 production in clinical malaria in
endemic settings, we cultured PBMC from Indonesian patients402 Cell Reports 17, 399–412, October 4, 2016naturally infected with P. falciparum
(Table 2). Cells were isolated at the time
of admission and 7 days after commence-ment of drug treatment. Parasite-specific IL-10 was detected at
both time points, and blockade of type I IFN signaling resulted in
reduced IL-10 levels 7 days after commencement of drug treat-
ment (Figure 7F), as previously observed in healthy volunteers
(Figure 7A). Hence, type I IFN-dependent, parasite-specific IL-
10 production was a feature of anti-parasitic immunity after
administration of anti-parasitic drug, and altogether, these
data show that type I IFN-dependent IL-10 production by
CD4+ T cells has important functional consequences for devel-
oping anti-parasitic immunity.
DISCUSSION
In this study, we identified three distinct phases of immune regu-
lation mediated by type I IFNs during blood-stage P. falciparum
infection of humans involving innate immune cells, effector CD4+
T cells, and anti-inflammatory Tr1 cells. In each of these phases,
type I IFNs suppressed infection-induced inflammation. This
included inhibiting production of the pro-inflammatory cytokines
IL-6, IL-1b, IL-17, and IFNg but not of TNF. Surprisingly, we
found no correlation between parasite-specific type I IFN pro-
duction and either parasite burden or IFNg or IL-10 production
in our studies, suggesting complex regulatory networks being
mediated by this family of cytokines. We were unable to detect
any cytokines directly in serum before drug treatment and
were thus limited in our examination of relationships between
type I IFNs and pro-inflammatory cytokine production. Type I
IFNs have been shown to inhibit the activity of various innate im-
mune cells, includingmacrophages, monocytes, and neutrophils
(Auerbuch et al., 2004; Berry et al., 2010; Carrero et al., 2004;
Desvignes et al., 2012; Parker and Prince, 2012; Stanley et al.,
2007; Xin et al., 2010). Previous studies in mouse models of ma-
laria showed direct suppressive effects of type I IFNs on tissue
resident DC subsets, associated with changes in co-stimulatory
Figure 3. Blood-Stage P. falciparum Induces a Type I IFN Response that Suppresses IFNg Production
(A) PBMCs were isolated from volunteers 7 days p.i. and cultured in the presence of nRBCs, pRBCs, or pRBCs + anti-IFNAR antibody or its isotype control for
72 hr, and then IFNg levels were measured in cell culture supernatants (cohorts 6 and 7; n = 12).
(B) PBMCs were isolated from participants 7 days p.i. and cultured in the presence of nRBCs, pRBCs, pRBCs + anti-IFNAR, or pRBCs + anti-IFNAR + anti-HLA-
DR antibody, as well as the relevant isotype controls, for 72 hr, and then IFNg levels were measured (cohorts 6, 7, 9, and 10; n = 25).
(C) Linear regression analysis was performed to determine the correlation between log-transformed IFNg levels and blood parasitemia using the AUC values from
qPCR measurements of parasite numbers (cohorts 6–10; n = 29). D7, day 7. p < 0.0001, linear regression function (goodness of fit).
(D) PBMCs were isolated from volunteers 7 days p.i. and cultured in the presence of pRBCs + anti-IFNAR antibody or its isotype control for 72 hr, and then IFNg
levels measured by intracellular cytokine staining, in which the IFNgMFI on IFNg+ CD4+ and CD8+ T cells, CD56+ CD3 (NK) cells, CD56+ CD3+ cells, and CD3
CD56 (other) cells was determined using the GeoMean function in FlowJo (cohorts 7 and 10; n = 12).
Median + min and max (A, B, and D). ***p < 0.001, **p < 0.01, *p < 0.05, Wilcoxon matched-pairs signed rank test.molecule expression and increased DC IL-10 production (Haque
et al., 2014). Although wewere unable to examine tissue resident
DCs in the CHMI studies undertaken here, we found that type I
IFNs suppressed IL-6 production by blood monocytes, suggest-
ing these cells are an important target during blood-stage ma-
laria. Monocytes play protective roles during malaria through
phagocytosis of pRBC, antibody-dependent cell inhibition, and
production of pro-inflammatory cytokines (Chua et al., 2013;Sheel and Engwerda, 2012). Furthermore, IL-6, along with
TGF-b, is important for IL-17 production (Bettelli et al., 2006;
Mangan et al., 2006; Veldhoen et al., 2006), and the suppression
of both IL-6 and IL-17 identifies amajor immunological axis regu-
lated by type I IFNs during blood-stage P. falciparum infection.
In addition to suppressive effects onmonocytes,weobserveda
profound impact of type I IFNs on antigen-specific IFNg produc-
tion by CD4+ T cells in pre-symptomatic P. falciparum-infectedFigure 4. Type I IFNs Suppress IL-6, IL-1b,
and IL-17, but Not TNF Production in
Response to P. falciparum
(A–D) PBMCs were isolated from volunteers on days
0, 7, 14, and 28 p.i. and cultured in the presence of
nRBCs, pRBCs, or pRBCs + anti-IFNAR antibody or
its isotype control for 72 hr beforemeasuring IL-6 (A),
IL-1b (B), IL-17 (C), or TNF (D) levels.
Data from cohorts 6 and 7; n = 12. Mean ± SEM.
***p < 0.001, *p < 0.05, Wilcoxon matched-pairs
signed rank test.
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Figure 5. Type I IFNs Suppress Monocyte-
Derived IL-6 Production in Response to
P. falciparum
(A) Flow cytometry gating strategy is shown for
pDCs and mDCs (top row) and for monocytes (bot-
tom row) (cohort 6; n = 7).
(B–D) Isolated PBMCswere cultured in the presence
of pRBCs + anti-IFNAR antibody or its isotype
control for 24 hr, and then BFA added for the last
3 hr. IL-6 was measured by intracellular cytokine
staining and flow cytometry. IL-6 MFI on pDCs (B),
mDCs (C), and monocytes (D) at days 0 and 7 p.i. is
shown (cohort 6; n = 7).
Median + min and max. **p < 0.01, Wilcoxon
matched-pairs signed rank test.volunteers. This finding is in line with our previous work in
mousemodelsofmalaria, inwhichweobserved type I IFN-depen-
dent suppression of anti-parasitic CD4+ T cell responses (Haque
et al., 2011, 2014). In the absence of type I IFN signaling blockade,
parasite-specific IFNg production 7 days after inoculation was
no different from background levels detected before infection,
consistent with little detectable inflammatory signature in
subjects with sub-microscopic, pre-symptomatic P. falciparum
infection at this time point. However, parasite-induced type I
IFNs were readily detected at this time, and blockade of
type I IFN signaling caused greatly enhanced MHC class II-404 Cell Reports 17, 399–412, October 4, 2016restricted IFNg production, as well as pro-
duction of several other potent inflamma-
tory cytokines, with the exception of TNF.
IFNg production in response to parasite
antigen was highly variable among cohorts
at day 7 p.i., and we attribute this to the
varied timing of blood sampling in relationto the parasite life cycle and, in particular schizogony and
RBC rupture, when we anticipate a spike in inflammation. Never-
theless, our data indicate that type I IFNs play an important
role in suppressing inflammation during sub-microscopic, pre-
symptomatic P. falciparum infection, and given the reported
importance of IFNg production for control of blood-stage malaria
parasites (McCall et al., 2010; Meding et al., 1990; Shear et al.,
1989; Stevenson et al., 1990; Su and Stevenson, 2000; van der
Heyde et al., 1997; Yoneto et al., 1999), these findings identify a
potent mechanism for the early suppression of anti-parasitic
immunity.Figure 6. Blood-Stage P. falciparum Induces
HLA-DR Restricted Tr1 Cells and IL-10 Pro-
duction
(A) PBMCs were isolated from volunteers at days 0,
7, 14, and 28 p.i. and cultured in the presence of
nRBCs or pRBCs for 72 hr, and then cell culture
supernatants were harvested and IL-10 levels were
measured (cohort 6; n = 7).
(B) PBMCs were isolated from volunteers 14 days
p.i. (7 days after drug treatment) and cultured in
the presence of nRBCs, pRBCs, or pRBCs + anti-
HLADR antibody or its isotype control for 72 hr. BFA,
PMA, and ionomycin were added for the remaining
3 hr of culture. Representative gating strategy from
left to right shows lymphocytes, live or viable cells,
CD16 CD56 (exclusion of NK and gd T cells),
CD3+, CD4+, and IFNg+ IL-10+ (cohorts 10 and 11;
n = 10).
(C and D) The frequency of Tr1 cells was measured
by flow cytometry (C), and IL-10 levels were
measured in cell culture supernatants (D) (cohorts 10
and 11; n = 10).
Mean ± SEM (A), median + min and max (C and D).
**p < 0.01, *p < 0.05, Wilcoxon matched-pairs
signed rank test.
Figure 7. Type I IFNs Promote Tr1 Cell Devel-
opment and IL-10 Production after Drug
Treatment in Volunteers Infected with
P. falciparum and Malaria Patients with Natu-
ral P. falciparum Exposure
(A) PBMCs were isolated from volunteers at day 14
p.i. (7 days after drug treatment) and cultured in the
presence of pRBCs + anti-IFNAR antibody or its
isotype control for 72 hr before measuring IL-10
levels (cohorts 6 and 7; n = 12).
(B) PBMCs were isolated from volunteers 14 days
p.i. (7 days after drug treatment) and cultured in the
presence of nRBCs, pRBCs, or pRBCs + anti-IFNAR
antibody or its isotype control for 72 hr. BFA, PMA,
and ionomycin were added for the remaining 3 hr
of culture before frequencies of Tr1 cells were
measured by flow cytometry (cohort 7; n = 5).
(C) Linear regression analysis was performed to
determine the correlation between log-transformed
IL-10 levels and blood parasitemia using the
AUC values from qPCR measurements of parasite
numbers (cohorts 6–10; n = 29). D14, day 14.
p < 0.01, linear regression function (goodness of fit).
(D and E) PBMCs were isolated from volunteers
14 days p.i. (7 days after drug treatment) and
cultured in the presence of pRBCs + anti-IL-10
antibody or its isotype control for 72 hr, and then
IFNg levels (D) and TNF levels (E) were measured
(cohorts 7 and 8; n = 9).
(F) Cryopreserved PBMCs from malaria patients in-
fected with P. falciparum from Timika, Indonesia,
taken at time of admission into the clinic (day 0) and
7 days after commencement of drug treatment (day 7) were thawed and cultured in the presence of nRBCs, pRBCs, or pRBCs + anti-IFNAR antibody or its isotype
control for 72 hr, and then IL-10 levels were measured.
Median + min and max (A, B, and D–F). ***p < 0.001, **p < 0.01, *p < 0.05, Wilcoxon matched-pairs signed rank test.An emerging paradigm in the evolution of anti-pathogen
cellular immunity is the development of self-regulating T cell sub-
sets during established infection (Belkaid and Rouse, 2005; Eng-
werda et al., 2014; Jankovic et al., 2010; O’Garra et al., 2004). Tr1
cells are one such cell population that arises from anti-parasitic
Th1 cell responses, and their production of IL-10 appears to be a
major mechanism of immune regulation (Anderson et al., 2007;
Couper et al., 2008; Jankovic et al., 2007; Nyle´n et al., 2007).
IL-10 acts on multiple levels of cellular immune responses,
including antigen processing, production of cytokines, and
various anti-microbial products (Saraiva and O’Garra, 2010), as
well as the expression of inhibitory receptors such as PD-1,
TIM-3, and LAG-3 (Camisaschi et al., 2010; Ha et al., 2008; Jin
et al., 2010). These actions of IL-10 can favor persistence of
pathogens, but IL-10 also protects against tissue damage and
associated disease (Jankovic et al., 2007; Montes de Oca
et al., 2016; O’Garra et al., 2004). Tr1 cells are prevalent in chil-
dren living in malaria-endemic regions (Jagannathan et al.,
2014; Portugal et al., 2014; Walther et al., 2009), and results pre-
sented here not only demonstrate the emergence of Tr1 cells af-
ter resolution of first blood-stage P. falciparum infection but also
show that the IL-10 produced by these cells potently suppressed
parasite-specific, pro-inflammatory cytokine production. Thus,
we identify type I IFNs as important regulators of IL-10 produc-
tion both in infected study subjects and in patients living in ma-
laria-endemic areas.One finding in our study was the development of readily de-
tected, parasite-specific Tr1 cells 7 days after commencement
of drug treatment in subjects with their first P. falciparum infec-
tion. This occurred alongside the development of a robust Th1
cell response, presumably as a result of available parasite anti-
gen caused by drug-mediated killing. The rapid development
of immunoregulatory networks following a single exposure to
the parasite highlights the potential of these regulatory networks
to influence subsequent immunity, particularly to vaccines.
Hence, our findings indicate that incorporating inhibitors of spe-
cific immune checkpoints into vaccine formulations may be one
way to transiently reduce immune suppression and thus allow
generation of robust vaccine-mediated, anti-parasitic immunity.
However, given potential differences in the immunobiology re-
sulting from intravenous challenge with parasites, compared
with mosquito-transmitted parasites, and in particular changes
in parasite virulence (Spence et al., 2013), it will be important
to evaluate these strategies in the context of natural infection.
In summary, we have identified type I IFNs as powerful inhib-
itors of innate and adaptive immune responses following first
exposure to P. falciparum. Our results support the idea that the
early establishment of immunoregulatory networks following
infection may act to suppress subsequent immune responses
to new infections. These findings not only provide insights into
how immune responses develop and are regulated during ma-
laria but also help identify strategies to improve vaccines andCell Reports 17, 399–412, October 4, 2016 405
Table 1. Cohorts Used in These Studies
Study Cohort Trial Registration Year of Study Trial Drug Study Cohort Subject Age (Years) Gender
1 ACTRN12612000323820 2012 1 S001 31 M
S006 23 M
S011 26 M
2 2012 2 S015 20 F
S016 27 M
S017 22 F
S018 24 F
S019 20 F
S020 24 F
S022 23 M
S025 25 M
3 2012 3 S028 28 F
S032 27 F
S033 28 M
S035 25 M
S036 25 F
S038 37 M
S041 25 F
S042 34 M
4 ACTRN12612000814875 2012 1 S005 22 F
S009 23 M
S011 28 F
S012 25 M
S013 32 F
S017 16 M
S018 34 M
5 2012 2 S024 20 M
S026 27 M
S027 27 F
S028 27 M
S029 35 M
S031 23 F
S032 23 M
6 ACTRN12613001040752 2013 1 S001 25 M
S002 22 M
S003 24 F
S007 22 F
S008 27 M
S009 41 F
S010 26 F
7 ACTRN12613000565741 2014 3A S030 25 M
S033 21 F
S035 23 M
S036 26 F
S037 21 F
8 2014 3B S045 18 M
S050 22 F
S052 32 F
S057 23 M
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Table 1. Continued
Study Cohort Trial Registration Year of Study Trial Drug Study Cohort Subject Age (Years) Gender
9 NCT02281344 2014 1 S001 29 M
S002 28 M
S005 29 M
S006 24 M
S008 23 M
S011 19 M
10 NCT02389348 2015 1 S018 37 M
S019 55 M
S020 22 M
S017 25 M
S011 21 F
S021 19 F
S007 24 F
11 2015 2 S028 27 F
S029 23 M
S022 24 F
n = 65. F, female; M, male.other therapies aimed at preventing, and ultimately eradicating,
one of the most important parasitic diseases.
EXPERIMENTAL PROCEDURES
CHMI Studies
The work described here comprises studies performed nested within a series of
clinical trialsdesigned to test theanti-malarial activityof variousnewlydiscovered
anti-malarial drugs (Table 1) against early blood-stage P. falciparum infection in
healthy individuals. The studieswere undertaken at Q-Pharm under the approval
of the QIMR Berghofer Human Research Ethics Committee (QIMR-HREC). All
studies were registeredwith the Australian andNewZealandClinical Trial Regis-
tration scheme (ANZCTR: ACTRN12612000323820, ACTRN12612000814875,
ACTRN12613000565741, and ACTRN12613001040752) or the U.S. NIH
ClinicalTrials.gov (NCT:NCT02281344,andNCT02389348). Thestudies involved
the collection of blood (20–40mL) at various time points, including days 0 (before
challenge), 7, 14, and 28–35, to assess cellular immune responses. Participants
were healthy males and females between 18 and 55 years of age with no prior
exposure to malaria or residence in malaria-endemic regions. All participants
were infected intravenously withP. falciparum (clone 3D7, drug-sensitive strain),
which results in inducedblood-stagemalaria (IBSM) challenge. Real-time qPCR,
asdescribedbyRockett et al. (2011), was used tomonitor peripheral parasitemia
twice daily beginning 4 days after inoculation. Drug was administered once
parasitemia had exceededR1,000 parasites/mL, and participants were moni-
tored closely for 48 hr as in-patients. Although the aim was to minimize subject
symptoms, some participants reported headaches, nausea, vomiting, and
increased body temperature, all of which may have been related to symptoms
of early P. falciparum infection.
Clinical Malaria
PBMCs were isolated from 12 adult patients attending primary health care
clinics with uncomplicated P. falciparum malaria in Timika, Papua, Indonesia
(Ratcliff et al., 2007), a region of unstable malaria transmission (Karyana
et al., 2008). Patient clinical data for samples from Timika are shown in Table 2.
Median age was 34 years (range 20–43 years). Nine patients (75%) were male,
with half of Papuan Highlander ethnicity and half non-Papuan. Median parasi-
temia was 2,195 parasites/mL (interquartile range [IQR] 810.75–4640.25 para-
sites/mL), with 11 patients (92%) treated with artemisinin combination therapy
and one patient (8%) treated with chloroquine plus sulfadoxine-pyrimeth-amine. PBMCswere cryopreserved on the day of presentation and 7 days after
treatment.
Human PBMC Isolation
Human PBMCs were isolated by Ficoll-gradient separation from whole blood.
Briefly, 20–40 ml of blood was collected into lithium heparin tubes (BD Biosci-
ences). Whole blood was inverted gently a few times before centrifugation at
784 3 g for 10 min at room temperature to remove 1–2 ml of plasma, which
was stored at 20C to 80C until required. After plasma removal, 25 ml of
sterile 13 PBS (QIMR Berghofer) was added, and the tubes were inverted
gently a few times to ensure a homogenous mixture. Then, 13 ml of Ficoll-Pa-
que Plus (GE Healthcare) was layered gently under the blood and centrifuged
at 3923 g for 30 min at room temperature without brake. After centrifugation,
the buffy coat was collected, and then PBMCs were washed with 50 ml of 13
PBS and centrifuged at 392 3 g for 10 min at 4C. The PBMC pellet was then
re-suspended in 4 ml complete media. Cells were diluted 1:10 in 0.1% trypan
blue in PBS (0.4%; MP Biomedicals) and counted on a hemocytometer (Blau-
brand counting chamber; Neubauer).
PBMC Assay
PBMCs were isolated as described as earlier, counted on the hemocytome-
ter, and then adjusted to a concentration of 2 3 106 cells/mL in complete
media: 45 ml of RPMI 1640, 5 ml of fetal calf serum (FCS), and 20 mL of
gentamicin. For cryopreserved samples (field samples collected from Timika,
Indonesia) (Figure 3B), each vial underwent a quick thaw procedure (37C for
5 min in the water bath). Once samples were thawed, complete media was
added drop-wise (1 ml), followed by the addition of 9 ml of media. Cells
were centrifuged for 600 3 g for 7 min at room temperature. Cells were
then counted, and the viability of the cells was determined on the hemocy-
tometer. All samples were adjusted to a concentration of 2 3 106 cells/mL
in complete media.
Both nRBCs and pRBCs were prepared as follows for use as antigen in the
PBMC assay, which was set up in a 96-well U-bottom plate. Cryopreserved
stocks of nRBCs and pRBCs were allowed to thaw on ice and then adjusted
to aworking concentration of 93 106 nRBCs or pRBCs/mL in completemedia.
Then, 25 mL of this working stock was added to each corresponding well (for a
final concentration of 1 3 106 nRBCs or pRBCs/mL). As a positive control,
25 mL of a mitogen, phytohemagglutinin (PHA, final concentration 10 mg/mL;
Sigma-Aldrich), was added into corresponding wells. After all antigens andmi-
togens had been plated out, 200 mL of PBMCs (final concentration of 4 3 105Cell Reports 17, 399–412, October 4, 2016 407
Table 2. Timika Patient Clinical Data
Age (Years) Gender Weight (kg) Ethnicity Treatment
43 F 55 non-Papuan Artekin (dihydroartemisinin and piperaquine)
43 M 51 non-Papuan Coart (artemether and lumefantrine)
30 M 45 Highland Coart
25 M 46 non-Papuan Coart
27 M 49 Highland Coart
35 F 71 non-Papuan Coart
37 M 55 non-Papuan Artekin
20 M 59 Highland Artekin
36 M 59 Highland Coart
20 M 49 Highland Coart
33 M 47 non-Papuan Coart
40 F 55 Highland Cq+SP (chloroquine and sulfadoxine-pyrimethamine)
All patients were P. falciparum positive. F, female; M, male.cells/well) were added to each respective well. The following blocking antibody
treatments were then added: human anti-IFNa/b receptor chain 2 antibody
(clone MMHAR-2, final concentration of 5 mg/mL; Merck) or its mouse IgG2A
isotype control (clone 20102, final concentration of 5 mg/mL; R&D Systems),
human anti-IL-10 antibody (clone 25209, final concentration of 20 mg/mL;
R&D Systems) or its mouse IgG2B isotype control (clone 20116, final concen-
tration of 20 mg/mL; R&D Systems), and Ultra-LEAF (low endotoxin, azide free)
purified anti-human HLA-DR antibody (clone L243, final concentration of
20 mg/mL; BioLegend) or its Ultra-LEAF purified mouse IgG2a, k isotype con-
trol (clone MOPC-173, final concentration of 20 mg/mL; BioLegend). The plate
was then placed in a humidified incubator at 37C, 5% (v/v) CO2 for 24–72 hr.
Culture supernatants were harvested at 24 and 72 hr post-PBMC re-stimula-
tion and stored at 20C until required.
Flow Cytometry
Intracellular cytokine analysis for IFNg and IL-10 was performed 72 hr after
PBMC re-stimulation. Briefly, for detection of ex vivo IFNg alone, 10 mg/mL
of brefeldin A (BFA; Sigma-Aldrich) was prepared in complete media, with
10% fetal bovine serum (FBS), and added to each well for the remaining 3 hr
(at 69 hr) of re-stimulation. To detect Tr1 cells (IFNg+IL-10+), 10 mg/mL of
BFA, 25 ng/mL of phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich),
and 500 ng/mL of ionomycin calcium salt (Sigma-Aldrich) were prepared in
complete media (with 10% FBS) and added to each well for the remaining
3 hr of re-stimulation. Then, 72 hr after re-stimulation, PBMCs were washed
with Hank’s balanced salt solution (HBSS; Life Technologies) and centrifuged
at 3383 g for 3 min at 4C. Next, 1 mg/mL (in a final volume of 50 mL) of Zombie
near infrared (NIR) fixable viability kit (BioLegend) was diluted in HBSS, added
to eachwell, and incubated for 15–20min at room temperature, protected from
light. PBMCs were washed with HBSS and centrifuged at 3383 g for 3 min at
4C. Then, 1–5 mg/mL (in a final volume of 50 mL) of surface antibodies were
diluted in FACS buffer, added to each well, and incubated for 15–20 min on
ice, protected from light. PBMCs were then washed twice with 150–200 mL
of FACS buffer and centrifuged at 338 3 g for 3 min at 4C. Next, 100 mL of
BD Cytofix buffer (BD Biosciences) was added to each well and incubated
on ice for 20 min, protected from light. PBMCs were then washed twice with
100–200 mL of 13 BD Perm buffer (BD Biosciences) and then centrifuged at
338 3 g for 3 min at 4C. Then, 2 mg/mL (final volume of 50 mL) of intracellular
antibody (IFNg PeCy7 and IL-10 PE), diluted in BD Perm buffer was added per
well and incubated on ice for 60 min, protected from light. PBMCs were then
washed twice with 150–200 mL of 13 BD Perm buffer and centrifuged at 3383
g for 3min at 4C. PBMCswere re-suspended in a final volume of 100 mL of 1%
paraformaldehyde (PFA; MP Biomedicals), stored at 4C, and protected from
light until acquisition on a laser (LSR) Fortessa 5 (BD Biosciences). Samples
were generally acquired within 12–24 hr post-staining. CD4+ T cells were
defined as CD16 CD56 CD3+ CD4+, CD8+ T cells were defined as CD16408 Cell Reports 17, 399–412, October 4, 2016CD56 CD3+ CD8+, NK cells were defined as CD16 CD56+ CD3, pDCs
were defined as CD3 CD19 CD56 CD14 CD16 HLA-DR+ CD123+
CD11c, myeloid derived dendritic cells (mDCs) were defined as CD3
CD19 CD56 CD14 CD16 HLA-DR+ CD123 CD11c+, monocytes were
defined as CD56 CD3 CD19 HLA-DR+ CD14+ or CD16+, and B cells
were defined as CD56 CD3 CD19+.
Detection of IFNa by Intracellular Cytokine Staining
For detection of IFNa, PBMCs were stimulated with nRBC, pRBC, or 50 mg/mL
of CpG (ODN2216; InvivoGen) for 2 hr, and BFA was added for the remaining
4 hr of stimulation. Then, 6 hr after re-stimulation, PBMCs were washed with
HBSS and centrifuged at 3383 g for 3 min at 4C. Next, 1 mg/mL (in a final vol-
ume of 50 mL) of Zombie NIR fixable viability kit was diluted in HBSS, added to
each well, and incubated for 15–20 min at room temperature, protected from
light. PBMCs were washed with HBSS and centrifuged at 3383 g for 3 min at
4C. Then, 1–5 mg/mL (in a final volume of 50 mL) of surface antibodies were
diluted in FACS buffer and Brilliant stain buffer (Cat# 563794; BD Biosciences),
added to each well, and incubated for 30 min at 37C, protected from light.
PBMCs were then washed twice with 150–200 mL of FACS buffer and centri-
fuged at 3383 g for 3 min at 4C. Next, 100 mL of BD Cytofix buffer was added
to each well and incubated on ice for 20 min, protected from light. PBMCs
were then washed twice with 100–200 mL of 13 BD Perm buffer and centri-
fuged at 3383 g for 3 min at 4C. Then, 5 mg/mL (final volume of 50 mL) of intra-
cellular antibody (IFNa PE), diluted in BD Perm buffer, was added per well and
incubated at room temperature for 45–60 min, protected from light. PBMCs
were then washed twice with 150–200 mL of 13 BD Perm buffer and centri-
fuged at 3383 g for 3 min at 4C. PBMCs were re-suspended in a final volume
of 100 mL of 1% PFA, stored at 4C, and protected from light until acquisition
on a LSR Fortessa 5.
PerCP/Cy5.5-conjugated anti-BDCA-1 (L161, 1:50), anti-CD8 (SK1, 1:80),
PerCP/Cy5.5-conjugated anti-CD56 (HCD56, 1:25), phycoerythrin-dazzle
594-conjugated anti-CD123 (6H6, 1:50), brilliant violet 421-conjugated
anti-CD1c (BDCA-1) (L161, 1:50), brilliant violet 785-conjugated anti-CD303
(BDCA-2) (201A, 1:25), phycoerythrin-Cy7-conjugated anti-CD304 (BDCA-4)
(12C2, 1:25), brilliant violet 650-conjugated anti-CD16 (3G8, 1:25), allophyco-
cyanin-conjugated anti-CD141 (M80, 1:25), Alexa Fluor 700-conjugated anti-
CD3 (SK7, 1:50), anti-CD16 (3G8, 1:50), fluorescein isothiocyanate-conjugated
anti-CD3 (SK7, 1:200), brilliant violet 605-conjugated anti-CD19 (H1B19, 1:20),
phycoerythrin-Cy7-conjugated anti-CD123 (6H6, 1:50), and allophycocyanin-
conjugated PD1 (EH12.2H7, 1:20) were purchased from BioLegend. Allo-
phycocyanin-Cy7-conjugated anti-CD4 (RPA-T4, 1:25), anti-HLA-DR (L243,
1:30), Horizon V500-conjugated anti-CD4 (RPA-T4, 1:30), Alexa Fluor 700-
conjugated anti-CD11c (B-ly6, 1:50), fluorescein isothiocyanate-conjugated
anti-CD19 (SJ25C1, 1:20), phycoerythrin-Cy7-conjugated anti-CD45RA
(HI100, 1:20), anti-IFNg (4S.B3, 1:100), phycoerythrin-conjugated anti-IL-6
(MQ2-13A5, 1:20), anti-IL-10 (JES3-19F1, 1:100), brilliant violet 421-conju-
gated anti-CD56 (NCAM16.2, 1:20), anti-CXCR3 (1C6/CXCR3, 1:20), and
anti-CXCR5 (RF8B2, 1:20) were purchased from BD Biosciences. Qdot 605-
conjugated anti-CD14 (T€uK4, 1:100) was purchased from Invitrogen (Molecular
Probes). Phycoerythrin-conjugated anti-IFNa (LT27:295, 1:10) was purchased
from Miltenyi Biotec. Dead cells were excluded from the analysis using LIVE/
DEAD Fixable Near Infra-Red Stain, (Invitrogen, Molecular Probes), according
to the manufacturer’s instructions.
MACS Purification of CD4+, CD56+, and CD14+ Cells
After isolation of PBMCs, the cells were washed in 10 ml of sterile Dulbecco’s
PBS (Life Technologies) and centrifuged at 3923 g for 10min at 4C to remove
any FBS carryover from the complete media. Magnetic-activated cell sorting
(MACS) Miltenyi bead kits (Miltenyi Biotec) were used for positive selection
of CD4+, CD56+, and CD14+ cells per manufacturer’s instructions. For the pos-
itive selection of CD4+ cells, after the first elution, the sample was loaded onto
a fresh column and then underwent a second round of elution to increase the
purity of selected population. Purity wasR95%–99%. Cells were washed with
9 ml of Dulbecco’s PBS and centrifuged at 3923 g for 10 min at 4C, and then
the pellet was gently re-suspended in 500 mL of RNA-later (Sigma-Aldrich).
Samples were transferred to 4C overnight and then to 80C for long-term
storage until RNA was extracted.
Real-Time qPCR
RNA was extracted from CD4+, CD56+, and CD14+ MACS-purified cells from
days 0, 7, and 10 p.i., using the RNeasy Plus Mini kit per manufacturer’s in-
structions (QIAGEN). RNA concentration and quality were determined using
the NanoDrop ND-1000 UV-Vis spectrophotometer (Thermo Scientific).
cDNAwas synthesized from total RNA using the High-Capacity cDNA Reverse
Transcription kit per manufacturer’s instructions (Applied Biosystems).
Primers for the following genes were purchased from Quantitect (QIAGEN),
ifna1, ifna2, ifna4, ifna5, ifna6, and ifnb. qPCRs were performed in duplicate,
using the GoTaq qPCR kit for SYBR green (A6001; Promega) on a CFX384
Touch Real-Time PCRDetection system (Bio-Rad) permanufacturer’s instruc-
tions. Values for each transcript were normalized to expression levels of the
GeoMean of two house-keeping genes: B2M (beta-2-microglobulin) and actin.
Fold change was then determined for each cell type and normalized to its cor-
responding day 0, using the 2DDCt method.
Calculating the IFNa Index
To determine whether there were differences in IFNa production on a per cell
basis, the IFNa index was calculated. Briefly, the frequency of IFNa+ events
was multiplied by the MFI of IFNa for each cell population.
Calculating the AUC
To determine whether there were associations between cytokines and para-
site growth, parasitemia was expressed as the AUC to determine a more ac-
curate indicator of parasite growth. Retrospective PCR parasitemia values
were tested in duplicate, and on the day of treatment, parasitemia was tested
in triplicate. AUC was only determined until drug treatment. The limit of detec-
tion (LOD) was assumed to be 64 parasites/mL (Rockett et al., 2011). After
initial data checks for potential outliers, values below the LOD (between 2
and 63) were substituted with LOD/2 (32) and values that were not detected
(ND) were set to 1. All parasitemia values were log-10 transformed, and the
mean of the log-10-transformed parasitemia was used as a summary measure
per time point per participant. All regression analyses were performed using
the mean log-10 parasitemia values and performed separately per participant.
The parasitemia growth can be modeled as a sine-wave function, though it re-
quires a minimum of six data points. Because most subjects (67%) had para-
sitemia data for fewer than six time points, the AUC was estimated using the
trapezoid rule, using GraphPad Prism v.6.
Statistical Analysis
Statistical differences between groups were determined using the Wilcoxon
matched-pairs signed rank test (day 0 versus day 7 or day 0 versus day 14),
and the linear regression function was used to analyze associations between
IL-10 or IFNg levels and the AUC by GraphPad Prism v.6 for Windows;p < 0.05 was considered statistically significant. All data are presented as
mean ± SEM unless otherwise stated.
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